BrainStorm Cell Therapeutics Inc.
Tel Aviv
462 articles about BrainStorm Cell Therapeutics Inc.
-
BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update
5/9/2023
BrainStorm Cell Therapeutics Inc. announced that it will hold a conference call to update shareholders on financial results for the First Quarter ended March 31, 2023, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, May 15th.
-
BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer
4/24/2023
BrainStorm Cell Therapeutics Inc. today announced the appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer (EVP, CMO), effective May 1, 2023.
-
BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update
3/30/2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022 and provided a corporate update.
-
The FDA has granted an advisory committee meeting for BrainStorm Cell Therapeutics’ investigational ALS therapy, NurOwn, the company announced Monday.
-
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS
3/27/2023
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the U.S. Food and Drug Administration will hold an Advisory Committee Meeting to discuss the company's Biologics License Application for NurOwn® for the treatment of amyotrophic lateral sclerosis.
-
BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update
3/21/2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time,
-
BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study
1/10/2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn's placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community.
-
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023
1/5/2023
BrainStorm Cell Therapeutics Inc. today announced that Chaim Lebovits , President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday, Jan. 9 at Biotech Showcase™ 2023.
-
BrainStorm Cell Therapeutics appoints a new co-CEO as it prepares for a January 11th Type A meeting for ALS hopeful NurOwn.
-
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer
1/4/2023
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced the promotion of Dr. Stacy Lindborg to the role of Co-Chief Executive Officer.
-
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn®
12/27/2022
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the U.S. Food and Drug Administration has granted a Type A meeting to discuss the contents of a refusal to file letter previously issued regarding the company's New Biologics License Application for NurOwn® for the treatment of ALS.
-
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration
12/12/2022
BrainStorm Cell Therapeutics Inc. today announced that the company has submitted a Type A Meeting Request to the U.S. Food and Drug Administration (FDA) to discuss the contents of a refusal to file letter previously issued by the FDA regarding the company's New Biologics License Application (BLA) for NurOwn® for the treatment of ALS.
-
Stevens Nation Responds to FDA's Refusal to File Letter, NurOwn Recipients Call for Advisory Committee Meeting
11/22/2022
Brainstorm Cell Therapeutics is seeking FDA approval of its mesenchymal stem cell therapy called NurOwn for the treatment of ALS.
-
During its third-quarter earnings call Monday, BrainStorm Cell Therapeutics emphasized its commitment to seek an advisory committee meeting for NurOwn in ALS.
-
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
11/14/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
-
BrainStorm Cell Therapeutics ran into another stumbling block with ALS hopeful NurOwn Thursday as the FDA issued a Refusal to File Letter for its Biologics License Application.
-
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
11/10/2022
BrainStorm Cell Therapeutics Inc. today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company's New Biologics License Application (BLA) for NurOwn for the treatment of ALS.
-
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
11/7/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, November 14, 2022.
-
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting
11/7/2022
BrainStorm Cell Therapeutics Inc. announced the presentation of a poster with new analyses from NurOwn's placebo-controlled Phase 3 amyotrophic lateral sclerosis trial that account for limitations in the Revised ALS Functional Rating Scale and provide evidence of a clinically meaningful treatment effect.
-
BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress
10/20/2022
BrainStorm Cell Therapeutics Inc. announced that a scientific abstract titled 'NurOwn Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers' will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held from October 26-28th in Amsterdam, NL.